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Abstract
Resistance to chemotherapy is a common problem en-
countered in the treatment of head and neck squa-
mous cell carcinoma (HNSCC). Chemoresistant HNSCC
tumors frequently overexpress antiapoptotic proteins,
such as Bcl-xL. ()-Gossypol, the negative enantiomer
of a cottonseed polyphenol, binds to Bcl-xL and was
recently been shown to inhibit HNSCC proliferation
in vitro. In this study, we assessed the in vivo effi-
cacy of ()-gossypol in an orthotopic xenograft model
of HNSCC, using two human HNSCC cell lines with
high Bcl-xL expression levels. Both produced tumors
in a murine floor-of-mouth model that mimics human
HNSCC, exhibiting growth and invasion into adjacent
tissues.Micewere randomized into threegroups: vehicle
control and two daily intraperitoneal ()-gossypol treat-
ment groups (5 and 15 mg/kg). Tumors were measured
twice weekly. In the control group, tumors grew pro-
gressively, whereas in ()-gossypol treatment groups,
tumor growth was significantly suppressed. The mitotic
rate in tumors from ()-gossypol–treated animals was
significantly lower than that in controls, and an increase
in the percentage of apoptotic cells was observed in
treated tumors versus controls. Residual tumors re-
mained growth-suppressed for 2 weeks after cessation
of ()-gossypol treatment. Our results demonstrate that
()-gossypol can inhibit tumor growth in an orthotopic
model of aggressive HNSCC.
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Introduction
In the United States, head and neck squamous cell carci-
noma (HNSCC) accounts for more deaths annually than
cervical cancer, melanoma, or lymphoma [1]. Aggressive
surgical treatment of HNSCC is physically and emotionally
debilitating. Chemotherapy (cisplatin), combined with radiation
therapy, has enabled some patients to avoid radical surgery
without altering disease prognosis [2]. However, the develop-
ment of resistance to chemotherapy limits the effectiveness of
such organ-sparing treatment approaches. Chemotherapeu-
tic agents, particularly DNA-damaging agents such as cispla-
tin, function by inducing apoptosis in cancer cells [3,4]. Thus,
dysregulation of apoptosis can lead to decreased tumor cell
death in response to chemotherapy and/or radiation. Over-
expression of the antiapoptotic protein Bcl-xL is common in
both HNSCC tumor samples [5] and HNSCC cell lines [6]. In
laryngeal cancer, high expression levels of Bcl-xL are associ-
ated with poor response to chemotherapy and radiation, requir-
ing subsequent laryngectomy [5]. Recently, we have shown
that high Bcl-xL expression directly correlates with resistance
to cisplatin treatment in HNSCC cells in vitro [7]. Hence, the
use of adjuvant agents that target antiapoptotic proteins in
HNSCC may overcome cisplatin resistance, and thus has the
potential to decrease patient morbidity and enhance survival.
Recently, a number of potential therapeutics targeting Bcl-2
family members have been described (reviewed in Fesik [8]).
()-Gossypol, a small-molecule Bcl-2 and Bcl-xL inhibitor, is
a polyphenol derived from cottonseed. Racemic gossypol,
composed of both ()-gossypol and (+)-gossypol, is used in
herbal medicines in China. Studies on melanoma, breast
Address all correspondence to: Nisha J. D’Silva, Department of Periodontics and Oral
Medicine, University of Michigan School of Dentistry, 1011 North University Avenue, Room
5217, Ann Arbor, MI 48109-1078. E-mail: njdsilva@umich.edu
1This research was supported by National Institute of Dental and Craniofacial Research
(NIDCR) grants DE00452-01 (N.J.D.), DE014620-01A1 (B.S.H.), and R01 DE13346 (T.E.C.);
National Cancer Institute (NCI) grant R01 CA83087 (C.R.B.); Department of Defense idea
grant BC000914; the Susan G. Komen Breast Cancer Foundation; the CapCure Foundation
(S.W.); the University of Michigan’s NCI Cancer Center support grant 5 P30 CA46592; Head
and Neck Cancer SPORE grant P50 CA97248; and NIDCD Research Center Core grant P30
DC05188 (multiple authors). S.J.W. and K.G.W. were funded by National Institutes of Health
training grant T32 DC05356. S.W. has financial interests in Ascenta Pharmaceuticals, which is
pursuing the production of ()-gossypol and other compounds for clinical use.
2Keith G. Wolter and Steven J. Wang contributed equally to this manuscript.
Copyright D 2006 Neoplasia Press, Inc. All rights reserved 1522-8002/06/$25.00
DOI 10.1593/neo.05691
Neoplasia . Vol. 8, No. 3, March 2006, pp. 163 – 172 163
www.neoplasia.com
RESEARCH ARTICLE
cancer, and colon cancers have shown that racemic gossy-
pol is well-tolerated and is moderately effective in reducing
tumor volume [9–12]. We and others [6,13] have shown that
()-gossypol, but not (+)-gossypol, binds to the BH3 pocket
of Bcl-xL. Furthermore, the negative, but not the positive,
enantiomer of gossypol effectively inhibits HNSCC cancer
cell growth in vitro [6,9,10,13].
In the current study, we investigated the potential of ()-
gossypol to suppress HNSCC tumor growth in an in vivo
orthotopic xenograft mouse model of aggressive human
head and neck cancer. Two cell lines representing laryngeal
cancer and oral cancer were used, and the ability of ()-
gossypol to suppress tumor cell growth as a single agent
was determined. Effects on tumor growth, mitotic activity,
and apoptosis were assessed.
Materials and Methods
Cell Culture
UM-SCC-17B and UM-SCC-1 HNSCC cell lines [14] were
cultured as described previously in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Grand Island, NY) contain-
ing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 50 mg/ml L-glutamine [15]. After appropri-
ate Institutional Review Board approval for Human Subject
Research had been obtained, primary oral keratinocytes
were cultured from human gingival tissues in keratinocyte
growth medium (KGM; Cambrex Corp., East Rutherford,
NJ), as described previously [16].
()-Gossypol Preparation
()-Gossypol was purified using the method described pre-
viously [6]. It was determined by high-pressure liquid chroma-
tography analysis to have a chemical purity of >97% and a
chiral purity of >95%.
Cell Proliferation/Viability Assay
Tostudy cell proliferation, cellswereplated at 100,000 cells/
well in six-well cell culture plates. After 36 to 48 hours of growth
in conditions mentioned above, the medium was replaced
with a 1:1 mixture of DMEM and KGM, supplemented with
()-gossypol at various concentrations. After 5 days, the num-
ber of viable cells was determined by trypan blue enumera-
tion assay. Cells were trypsinized, washed, and stained with
trypan blue, and then viable cells were counted using a
hemocytometer. Experiments were performed in triplicate.
Additionally, the MTT assay, which measures cell viability
basedon themitochondrial conversion of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) from a soluble
tetrazolium salt into an insoluble colored formazan precipi-
tate, followed by spectrophotometric quantification, was used
to verify trypan blue data. Cells were plated at 5000 cells/well
in 96-well plates, incubated overnight, and then treated with
a range of ()-gossypol concentrations. Sample plates were
incubated for 6 days in 300 ml of a 1:1 mixture of DMEM and
KGM containing ()-gossypol or solvent controls. MTT as-
says were then performed according to the manufacturer’s
protocol (RocheDiagnostics,Mannheim,Germany).Eachex-
perimental condition was repeated in 10wells, and the results
were averaged. Percent absorbance relative to control was
plotted as a linear function of drug concentration. Fifty per-
cent inhibitory concentration (IC50) was identified as the drug
concentration required to achieve 50% growth inhibition rel-
ative to untreated controls.
Immunodeficient Mouse Tumor Model
Six-week-old athymic nude mice (NCr-nu/nu strain; Na-
tional Cancer Institute, Frederick, MD) weighing 18 to 25 g
were anesthesized with 100 mg/kg ketamine and 10 mg/kg
xylazine, administered intraperitoneally. HNSCC cell lines,
grown to 50% to 70% confluence, were suspended in DMEM
at 1 to 3 million cells per 0.2 ml and injected submucosally in
the floor of the mouth. Using digital calipers, tumors were
measured biweekly in two dimensions, and tumor volume
was calculated using the formula: a a b / 2, where a is the
smaller dimension. Tumor cell dose was optimized for each
cell line to produce 4- to 5-mm tumors, corresponding to
tumors 35 to 60 mm3 in diameter, withinf2 to 3 weeks. Prior
to initiating treatment, the mice were randomly assigned to
three groups. ()-Gossypol was dissolved in ethanol, and
water was added to make a stock solution with a final etha-
nol content of 10%. Daily intraperitoneal administration of
5 mg/kg ()-gossypol, 15 mg/kg ()-gossypol, or 10% etha-
nol (vehicle control) was then initiated, with daily injection
volumes of approximately 200 ml per animal. The two ()-
gossypol dosage levels were chosen based on previous
studies, which suggested that these levels should be non-
toxic and potentially effective [17]; indeed, both dosages
were well tolerated by the mice in our study.
Tissue Microscopy
After euthanizing the mice, tumors were removed from
the animals and fixed in 10% formalin solution. Tissues were
paraffin-embedded, and 5-mm-thick sections were stained
with hematoxylin and eosin. To analyze mitotic rate in tumor
specimens, slides were scored by two independent inves-
tigators. Mitoses were counted in 20 high-power fields for
each specimen. Subsequently, the mitotic index (the average
number of mitoses per high-power field) was determined for
each tumor. For immunohistochemistry, paraffin-embedded
sections were deparaffinized and rehydrated. To examine
apoptosis in the specimens, sections were stained by termi-
nal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining using ApopTag Plus Assay system (Chem-
icon International, Temecula, CA), according to the manufac-
turer’s instructions. Ten high-power fields were examined for
each sample, and the number of cells staining positive in
each field was determined by a pathologist. Values were then
averaged to provide an apoptotic rate for each tumor speci-
men, and percentage (versus control) was determined for
each tumor group.
Statistical Analysis
Tumor growth rates were analyzed using a mixed-effects
model. The mixed-effects model combines fixed effects
164 In Vivo Effects of ()-Gossypol on Human Head and Neck Squamous Cell Carcinoma Wolter et al.
Neoplasia . Vol. 8, No. 3, 2006
(treatment group) with random effects (intercept at start of
treatment, growth rate per tumor) into a general linear model
framework. The size of the tumor within an animal is allowed
to have random deviation around a group mean, as well as
random deviation in the growth rate about a group mean. The
tumor growth rate was modeled using both a linear time ef-
fect (per day) and a quadratic time effect (per day squared).
However, only the linear time effect was significant in the
modeling process.
The values for the mitotic index and apoptotic scoring
were compared using Student’s t test for univariate analysis.
P < .05 was considered statistically significant.
Results
Cancer Cell Proliferation In Vitro Inhibited By
()-Gossypol Treatment
Prior to in vivo testing, we investigated the effects of ()-
gossypol on the growth of two HNSCC cell lines, UM-SCC-1
and UM-SCC-17B, as well as on primary normal human oral
keratinocytes in vitro. Both HNSCC cell lines expressed high
levels of Bcl-xL [6]. In the current study, we employed both
a direct measurement of viable cells by dye exclusion and
an indirect metabolic assay to assess cell growth inhibition
by ()-gossypol. Both tumor lines and normal keratinocytes
were grown in the presence or absence of varying con-
centrations of ()-gossypol (Figure 1) and showed dose-
dependent inhibition of cell growth over the range tested
(0–25 mM). Through the dye exclusion method, the IC50 for
both HNSCC cell lines was found to be approximately 4 mM
()-gossypol (Figure 1A). In contrast, normal keratinocytes
were less sensitive to ()-gossypol, with an IC50 of ap-
proximately 12.5 mM. Through the metabolic assay method,
the IC50 values for ()-gossypol were found to be 3, 6, and
17 mM for UM-SCC-1, UM-SCC-17B, and human oral kera-
tinocytes, respectively (Figure 1B). These results are con-
sistent with the selective growth inhibition of HNSCC cells
by ()-gossypol.
Optimization of the Xenograft Mouse Model
of Human HNSCC
The mouse floor-of-the-mouth model for human oral can-
cer was optimized for xenografts using the UM-SCC-17B and
UM-SCC-1 cell lines. We did not observe tumor encapsula-
tion—a difficulty that can be encountered at other injection
sites. Tumor doses of 1  106 and 2.5  106 cells for UM-
SCC-17B and UM-SCC-1, respectively, yielded 35- to
60-mm3-diameter tumors in the floor-of-the-mouth region at
2 to 4 weeks after injection. Histopathology was confirmed
by hematoxylin and eosin–stained sections of murine xeno-
grafts. UM-SCC-17B (Figure 2A) and UM-SCC-1 (Figure 2B)
xenografts exhibited morphologic and cytologic features con-
sistent with aggressive squamous cell carcinoma. UM-SCC-
17B (Figure 2A) exhibited infiltrating cords of tumor cells
invading skeletal muscles. Histopathological findings in-
cluded invasive sheets of neoplastic epithelial cells exhib-
iting nuclear pleomorphism, nuclear hyperchromatism, and
increasednumberofmitoses (Figure2A,arrows).Ofnote,UM-
SCC-1 exhibited areas of perineural invasion that are appar-
ent in a photomicrograph presented here (Figure 2B, arrows).
()-Gossypol Suppresses the Growth of UM-SCC-17B
and UM-SCC-1 Xenograft Tumors
Mice with UM-SCC-17B and UM-SCC-1 xenograft tumors
were treated with ()-gossypol to investigate its effects on
tumor growth in vivo (Figures 3 and 4, respectively). Thirty
mice were injected in the floor of the mouth with 1  106 UM-
SCC-17B cells. Eighteen days after tumor injection, mice
were randomized to three groups, and intraperitoneal in-
jections of 5 mg/kg ()-gossypol, 15 mg/kg ()-gossypol, or
drug vehicle solution were initiated (n = 10 in each group).
Tumor growth curves (tumor volume) for the mice up to day
35 are shown in Figure 3. For the control mice that received
the drug vehicle solution, there was progressive growth of
tumors (Figure 3A). In both 5 and 15 mg/kg ()-gossypol
treatment groups, a significant suppressive effect on tumor
Figure 1. Growth inhibition of HNSCC cells by ()-gossypol. (A) UM-SCC-17B
and UM-SCC-1 cell lines and primary human oral keratinocytes were con-
tinuously exposed to various concentrations of ()-gossypol over 5 days in a
medium composed of a 1:1 mixture of KGM and DMEM. Trypan blue viable
cell enumeration assays were performed in triplicate for each data point. Data
are expressed as percentages of untreated control values. Error bars indicate
standard deviation. (B) UM-SCC-17B and UM-SCC-1 cell lines and primary
human oral keratinocytes were continuously exposed to varying concentra-
tions of ()-gossypol over 6 days for MTT cell survival assays, performed in a
medium composed of a 1:1 mixture of KGM and DMEM (n = 10 for each point
on the graph). Data are expressed as percentages of untreated control values.
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growth was observed (Figure 3, B, C, and E); however, four
tumors in the treatment groups escaped: three at the lower
dose (Figure 3B) and one at the higher dose (Figure 3C ).
The mean tumor growth for the three groups of mice is
shown in Figure 3D. There was a significantly lower growth
rate for both the 5- and 15-mg/kg ()-gossypol– treated mice
Figure 2. UM-SCC-17B and UM-SCC-1 murine xenografts exhibit morphologic and cytologic features consistent with invasive squamous cell carcinoma.
Representative sections of hematoxylin and eosin–stained murine xenografts are shown. (A) UM-SCC-17B tumor exhibits neoplastic epithelial islands, some of
which invade skeletal muscle. Cytologic changes, including nuclear pleomorphism, nuclear hyperchromatism, and increased number of mitoses (arrows), are
observed. (B) UM-SCC-1 tumor exhibits areas of perineural invasion (arrows).
Figure 3. ()-Gossypol suppresses the growth of UM-SCC-17B xenograft mouse tumors. Thirty mice were injected with 1  106 UM-SCC-17B cells in the floor of
the mouth. Eighteen days after tumor injection, the mice were randomized to three groups (n = 10 in each group), and intraperitoneal injections of the drug vehicle
solution (A), 5 mg/kg ()-gossypol (B), or 15 mg/kg ()-gossypol (C) were initiated. Tumor growth curves (tumor volume) for the mice up to day 35 are shown. (D)
The mean tumor growth for the three groups of mice is shown. Error bars indicate standard deviation. There was a significantly lower growth rate for ()-gossypol –
treated mice (both 5 and 15 mg/kg) compared to that of control mice on day 28 (P V .008 and P V .006, respectively) and day 35 (P V .001 for both). The difference
in tumor growth between the 5- and the 15-mg/kg ()-gossypol groups was not significant. (E) Gross appearance of representative tumors from the control group
and the 15-mg/kg ()-gossypol treatment group, on the left and right, respectively, demonstrating the difference in tumor size between the untreated and the ()-
gossypol – treated animals.
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compared to the control mice. By day 28, control animals had,
on average, tumors that are 253mm3 (SE = 95, P = .008) and
268 mm3 (SE = 95, P = .006) larger than those in animals
treatedwith 5 and 15mg/kg ()-gossypol, respectively, as es-
timated by our regression model. On day 35, the average
tumor of the control animal was estimated to be 620 mm3
(SE = 164, P < .001) and 712mm3 (SE = 162, P < .001) larger
than the average tumor for animals treated with 5 and 15 mg/
kg ()-gossypol. Despite the greater number of ‘‘escapees’’
in the 5-mg/kg ()-gossypol group compared with that in the
15-mg/kg ()-gossypol group, the difference in tumor growth
between these two treatment groups was not significant.
In similar studies, 30 mice were injected with 2.5  106
UM-SCC-1 cells. Twenty-six days after tumor injection, once
the tumors had reached a diameter of 4 to 5 mm, the mice
were randomized to three groups, and daily intraperitoneal
injections of 5mg/kg ()-gossypol, 15mg/kg ()-gossypol, or
drug vehicle solution were initiated (n = 10 in each group).
Tumor growth curves for the mice up to day 43 are shown
in Figure 4. For the control mice that received the drug
vehicle solution, there was progressive growth of tumors
(Figure 4A). In both the 5- and the 15-mg/kg ()-gossypol
treatment groups, a suppressive effect on tumor growth was
observed (Figure 4, B and C, respectively). The mean tumor
growth for the three groups of mice is shown in Figure 4D.
()-Gossypol significantly suppressed tumor growth in both
the 5- and 15-mg/kg ()-gossypol– treated mice compared
to that in the control mice. By day 29, the average tumor for
animals treated with 5 or 15 mg/kg ()-gossypol was esti-
mated to be 57 mm3 (SE = 21, P = .009) and 53 mm3 (SE =
22, P = .016) smaller than that of the control animal. On
day 43, the difference was estimated to be 331 mm3 (SE =
48, P V .0001) and 315 mm3 (SE = 49, P V .001), for the
5- and the 15-mg/kg ()-gossypol groups, respectively, with
the average tumor of the treated animal being significantly
smaller than the average tumor of the control animal.
()-Gossypol Tumor Growth Suppression Is Sustained
Following Drug Withdrawal
Although tumor growth–suppressive effects in the ()-
gossypol groups were striking and highly significant when
compared to that in untreated controls, we noted that there
were small residual tumor masses in the mice. To determine
the effect of stopping ()-gossypol treatment, all treatments
were stopped on day 43 for three control and three ()-
gossypol– treated UM-SCC-1 tumors, and tumor measure-
ments were taken biweekly. The other mice in each of the
treatment groups and the vehicle control were euthanized
at this time point, and the tumors were harvested for his-
tology. The results of treatment cessation are illustrated in
Figure 5. For the ()-gossypol– treated mice, there was con-
tinued arrest of tumor growth for at least 2 weeks following
cessation of drug use, suggesting that the drug’s growth-
suppressive effects persist for a prolonged period. However,
after 2 weeks, the tumors grew progressively, and the mice
were euthanized on day 91. All the control mice had to be
euthanized by day 57 due to progressive tumor growth.
Mitotic Index Is Lower in ()-Gossypol–Treated Tumors
To investigate differences in proliferation between the con-
trol and the ()-gossypol– treated tumors, tumor sections
from each group were stained with hematoxylin and eosin
and examined in a blinded fashion for the number of mitotic
figures per high-power field (mitotic index). For each tumor
cell line, three control and six ()-gossypol–treated animals
Figure 4. ()-Gossypol suppresses the growth of UM-SCC-1 xenograft mouse tumors. Thirty mice were injected with 2.5  106 UM-SCC-1 cells in the floor of the
mouth. Twenty-six days after tumor injection, mice were randomized to three groups (n = 10 in each group), and intraperitoneal injections of the drug vehicle
solution (A), 5 mg/kg ()-gossypol (B), or 15 mg/kg ()-gossypol (C) were initiated. Tumor growth curves (tumor volume) for the mice up to day 43 are shown. (D)
The mean tumor growth for the three groups of mice is shown. Error bars indicate standard deviation. There was a significantly lower growth rate for ()-gossypol –
treated mice (both 5 and 15 mg/kg) compared to that in control mice on day 29 (P V .009 and P V .016, respectively) and day 43 (P V .0001 and P V .001,
respectively). The difference in tumor growth between the 5- and the 15-mg/kg ()-gossypol groups was not significant.
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were scored. In Figure 6, the mitotic indices for the control
and the treated UM-SCC-17B tumors are graphically rep-
resented. There was a statistically significant difference
(P < .01) between the mitotic indices of tumors in the control
mice (3.88 ± 1.27) and in the treated mice (1.48 ± 0.85). As
shown in the top panel of Figure 7, the mitotic indices for the
control and the ()-gossypol– treated UM-SCC-1 tumors are
2.35 ± 0.99 and 0.95 ± 0.82, respectively. Although not sta-
tistically significant, the trend for UM-SCC-1 was the same
as that for UM-SCC-17B, with treated cells displaying a
lower mitotic index. The lower panels of Figures 6 and 7
show a representative histology of treated and untreated
tumors, demonstrating disparity in mitoses (arrows) in rep-
resentative high-power fields.
Increase in Apoptosis in ()-Gossypol–Treated Tumors
To investigate the level of apoptosis occurring in the tumor
samples, tumor sections from each cell line (three control
and six treated) were TUNEL-stained. (Figure 8). The aver-
age number of apoptotic cells per field was 67% greater in
the treatment group that that in the untreated group for
UM-SCC-17B cell line tumors, and it was 28% greater in the
treatment group that that in the control group for UM-SCC-
1 cell line tumors. The difference was statistically significant
for UM-SCC-17B (P < .005), but not for UM-SCC-1.
Discussion
The treatment of advanced HNSCC remains a daunting clini-
cal problem. Despite an armamentarium that includes sur-
gery, radiation, and chemotherapy, survival in HNSCC has
not improved over the past four decades. A high Bcl-xL level
has been identified as a marker for the poor response of
HNSCC to chemotherapy. Previous work in breast, lung, and
prostate cancers has demonstrated that Bcl-xL overexpres-
sion facilitates tumor growth and mediates chemotherapy re-
sistance, presumably by inhibiting chemotherapy-induced
apoptosis [18–21]. This has led us to investigate the use of
Bcl-xL inhibitors as possible adjuvants to standard chemo-
therapy for the treatment of HNSCC.
Figure 5. ()-Gossypol treatment suppresses the growth of UM-SCC-1 xenograft mouse tumors after the cessation of ()-gossypol administration. Mice were
injected with 2.5  106 UM-SCC-1 cells in the floor of the mouth. Forty-three days after tumor injection, drug administration was stopped in three animals from the
control group (A) and in three animals from the 15-mg/kg ()-gossypol treatment group (B). (The remaining animals were euthanized at this time.) Animals were
followed, and tumors were measured until euthanization on day 57 for the control group (A) and on day 91 for the previously treated group (B). ()-Gossypol
suppression of tumor growth lasted several weeks after administration was stopped.
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Figure 6. Treatment of UM-SCC-17B tumors with ()-gossypol causes a significant decrease in the number of mitotic figures. (A) Graphic representation of mitotic
index in 20 high-power fields in control and ()-gossypol – treated tumors (P V .01). Error bars indicate standard deviation. Representative high-power fields from
control (B) and 15-mg/kg ()-gossypol (C) – treated UM-SCC-17B tumors, stained with hematoxylin and eosin. Arrows indicate mitotic figures.
Figure 7. Treatment of UM-SCC-1 tumors with ()-gossypol causes a decrease in the number of mitotic figures. (A) Graphic representation of mitotic index in 20
high-power fields in control and ()-gossypol – treated tumors. The decrease in ()-gossypol – treated tumors was not statistically significant. Error bars indicate
standard deviation. Representative high-power fields from control (B) and 15-mg/kg ()-gossypol (C) – treated UM-SCC-1 tumors, stained with hematoxylin and
eosin. Arrows indicate mitotic figures.
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Various potential strategies exist for modulating Bcl-xL
activity, including antisense nucleotides, antibodies, peptide in-
hibitors, and small molecules [22]. However, antisense nu-
cleotides, antibodies, and peptide approaches are limited by
poor in vivo stability, difficulties in tissue delivery, and/or high
costs. Small-molecule inhibitors are typically organic com-
pounds that bind to specific domains of a target protein.
Potentially, these compounds are advantageous due to supe-
rior in vivo stability, good cell permeability, and various possible
administrative routes [22]. In recent years, a number of differ-
ent small-molecule compounds, both naturally occurring and
synthetic, have been described as inhibitors of Bcl-xL [23–28].
Using a structure-based database screening approach, ()-
gossypol was identified as a small molecule with a particularly
high affinity for Bcl-xL. Gossypol is derived from a cottonseed
extract used in herbal medicines, and the racemic compound
has been studied for anticancer activity on a variety of
human tumors [9,11,12,15]. Prior studies from our laboratory
have demonstrated that ()-gossypol has an in vitro growth-
inhibitory effect against multiple human HNSCC cell lines, with
relatively little impact on normal fibroblasts or keratinocytes
[6]. Furthermore, we have shown that ()-gossypol induces
apoptosis in a high fraction of cells in cisplatin-resistant
HNSCC cell lines that overexpress Bcl-xL [6,7].
Cell culture studies allow rapid investigation of the effects
of novel agents on a variety of different cancers. However,
there are limitations to in vitro studies of anticancer agents.
These studies cannot evaluate the potential systemic toxicity
of the drug, or the role of the surrounding tissues in either the
growth of solid tumors or their responsiveness to the drug.
Clearly, in vivo experiments are important for the study of
new anticancer drugs prior to human clinical trials. Although
a variety of mouse models of HNSCC have been described,
studies have demonstrated advantages to orthotopic tumor
placement [29]. These include smaller tumor inocula, better
local tumor modeling, and patterns of regional and distant
metastasis analogous to human HNSCC. The floor-of-the-
mouth model is advantageous to the study of HNSCC, as the
tumors behave like human HNSCC, growing progressively
and invading surrounding tissues. We used an immuno-
deficient mouse model for our in vivo studies, in which cells
from two HNSCC tumor lines expressing high levels of Bcl-xL
were injected intraorally into submucosal tissues of the floor
of the mouth. Under optimized conditions, this tumor model
consistently produced tumors 35 to 60 mm3 in diameter
within 2 to 3 weeks of HNSCC cell inoculation. Accuratemea-
surement of tumors at the orthotopic site is further facilitated
by the hairless nature of the nude mouse. Tumors in the floor
of the mouth are well-tolerated by the mice. The orthotopic
xenograft system is thus a useful, reproducible model for the
in vivo evaluation of novel therapeutic agents for head and
neck cancer.
In this study, we show that ()-gossypol potently sup-
presses tumor growth in an immunodeficient mouse model
of human HNSCC. This growth inhibition was noted in
tumors arising from both HNSCC cell lines. The drug was
well-tolerated by the mice, with the only observed side effect
being moderate weight loss (<5%), which was reversible on
drug withdrawal. We used two ()-gossypol dosages for
both cell lines tested, but we observed no significant differ-
ences in tumor inhibition between the two dosing levels. Both
treatment levels were below the dosage established as the
maximum tolerated dose for mice [17]. Interestingly, follow-
ing drug withdrawal, there was arrest of tumor growth for
3 weeks. However, a small number of the treated mice had
persistent tumors, which, although derived from the same
HNSCC cell line, demonstrated resistance to the drug. The
tumors from these animals, referred to as ‘‘escapees’’ above,
are currently being analyzed to better elucidate potential
mechanisms of ()-gossypol resistance.
The fact that tumors in animals treated with ()-gossypol
demonstrate a decreased mitotic rate is intriguing. Other
studies have demonstrated that a number of chemothera-
peutic agents, both well-established and experimental, block
cell cycle progression and alter the activity of Bcl-xL and re-
lated proteins [30–32]. Likewise, antisense oligonucleotides
to Bcl-xL induce the growth arrest of tumor cells in vitro [33].
Our data suggest that the tumor cells are inhibited by ()-
gossypol from dividing. Although TUNEL staining indicates
that a modest increase in the apoptotic rate occurs in the
Figure 8. Treatment of UM-SCC-17B tumors with ()-gossypol leads to an increased rate of apoptosis, as indicated by TUNEL staining. (A) Control UM-SCC-17B
tumor from an animal that did not receive ()-gossypol. Note that there is positive staining in some cells (brown). (B) UM-SCC-17B tumor from an animal that
received 5 mg/kg ()-gossypol. Note the increase in the proportion of staining relative to (A).
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treated HNSCC tumors, the targeting of Bcl-xL by ()-
gossypol is unlikely to fully explain the dramatic inhibition
of tumor growth seen in the treatment groups. A number of
additional mechanisms have been described for gossypol-
mediated growth inhibition, including protein kinase C inhi-
bition [34], cellular metabolism blockade [35], modulation of
cyclin D1 and Rb [36], and generation of reactive oxygen
species [37]. It is likely that one or several of these mecha-
nisms contribute to the inhibition of HNSCC tumor growth
described here.
In this study, we demonstrate that ()-gossypol is an ef-
fective inhibitor of HNSCC growth at physiologically tolerable
doses. In this study, the antitumor growth effect of ()-
gossypol against HNSCC tumors, although significant, was
incomplete when it was used as a single agent. The com-
bination of ()-gossypol with standard chemotherapeutic
agents such as cisplatin may lead to a more dramatic reduc-
tion in tumors with reduced drug concentrations. A better
understanding of the mechanism of action of ()-gossypol
will facilitate the development of effective treatment proto-
cols when administered in conjunction with other chemo-
therapeutic agents. Indeed, ()-gossypol’s greatest utility
may lie in overcoming pathways of tumor drug resistance
and, therefore, may serve as an adjuvant to standard che-
motherapy regimens that have a different mechanism of
action. We have recently demonstrated that cisplatin treat-
ment of HNSCC cells in vitro selects for wild-type p53 and
high Bcl-xL expression, supporting the concept that Bcl-xL
protects tumor cells from cisplatin-induced apoptosis. Addi-
tionally, cisplatin-resistant tumor cells are very sensitive to
induction of apoptosis in response to treatment with ()-
gossypol [7].
Tumor resistance limits the effectiveness of conventional
therapy and underscores the need to target resistance path-
ways. ()-Gossypol, which works in part as a small-molecule
inhibitor of Bcl-xL, suppresses the growth of human HNSCC
cells in culture. Using a floor-of-the-mouth xenograft mouse
model of head and neck cancer, we demonstrate that ()-
gossypol also inhibits the growth of tumors in vivo. This novel
therapeutic agent has potential as an adjuvant to traditional
chemotherapy in the treatment of HNSCC.
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